Mariia Roman

About

Most faucets will allow you to claim once in a while. We are different, with us, you may decide how often you would like to claim. With every minute, every hour that passes, your claimable crypto amount fills up in our faucet. The initial increase being a lot faster and then slowing down over time until you make a claim.

Daily Bonus, and an extra bonus for Collecting ES COIN! Minimum 5 minutes between claims per account/IP address.

It currently stands at 98th rank in Fortune 500 ranking. Deere and Company agricultural products, usually sold under the John Deere name, include tractors, combine harvesters, balers, planters/seeders, ATVs and forestry equipment. The company is also a leading supplier of construction plant, as well as equipment used in lawn, grounds and turf care, such as ride-on lawn mowers, string trimmers, chainsaws, snow-throwers and for a short period, snowmobiles.

John Deere products are known for their distinctive green and yellow colour scheme. The company's slogan is "Nothing runs like a Deere" and has a picture of a Deer as a logo, a pun on "nothing runs like a Deer."

Additionally, John Deere manufactures engines used in heavy equipment and provides financial services and other related activities that support the core businesses.

History

Deere & Company began when John Deere, born in Rutland (town), Vermont, USA on February 7, 1804 moved to Grand Detour, Illinois in 1836 to escape bankruptcy in Vermont. Already an established blacksmith, Deere opened a 1,378 square feet shop in Grand Detour in 1837 which allowed him to serve as a general repairman in the village, as well as a manufacturer of small tools such as pitchforks and shovels.

Even more successful than these small tools was Deere's cast-steel plough, which was pioneered in 1837. Prior to Deere's introduction of the steel plough, most farmers used iron or wooden ploughs which stuck to the rich Midwestern soil and had to be cleaned very frequently. The smooth sided steel plough solved this problem, and would greatly aid migration into the American Great Plains in the 19th and early 20th century.

Deere's production of ploughs began slowly, but increased greatly when he departed from the traditional business model of making equipment as it was ordered and instead began to manufacture ploughs before they were ordered and then put them up for sale. This allowed customers to see what they were buying beforehand, and word of the product began to spread quickly.

Early Partnerships

In 1842, Deere entered a business partnership with Leonard Andrus and purchased land for the construction of a new two-story factory along the Rock River in Illinois. This factory, named the "L. Andrus Plough Manufacturer", produced about 100 ploughs in 1842 and approximately 400 ploughs during the next year. Despite the success, Deere's partnership with Andrus ended in 1848, when Deere relocated to Moline, Illinois in order to have access to the railroad and the Mississippi River. In Moline, Deere formed a partnership with Robert Tate and John Gould and quickly built a new 1,440 square feet factory in 1848. Production at the plant rose quickly and, by 1849, the Deere, Tate & Gould Company was producing over 200 ploughs a month, and a two story addition to the plant was built to allow for further production.

Deere & Company

John Deere bought out Tate and Gould's interests in the company in 1853, the same year that he was joined in the business by his son Charles Deere. The business continued to expand until 1857, when the company's production totals reached almost 1,120 implements per month. Then, in 1858 a nationwide financial recession took a toll on the company. In order to prevent bankruptcy, the company was reorganized and Deere sold his interests in the business to his son in law, Christopher Webber, and his son, Charles Deere, who would take on most of his father's managerial roles. The company was reorganized one final time in 1868, when it was incorporated as Deere & Company. The company's original stockholders were Charles Deere, Stephen Velie, George Vinton, and John Deere, who would serve as president of the company until 1886. Despite this, it was Charles who effectively ran the company. In 1869, Charles began to introduce marketing centres and independent retail dealers to advance the company's sales nationwide.

John Deere died in 1886, and the presidency of Deere & Company passed to Charles Deere. By now the company was manufacturing a variety of farm equipment products in addition to ploughs, including wagons, corn planters, cultivators. The company even expanded into the bicycle business briefly during the 1890s but the core focus of the company remained on agricultural implements. Increased competition during the early 1900s from the new International Harvester Company led the company to expand its offerings in the implement business, but it was the production of gasoline tractors which would come to define Deere & Company's operations during the twentieth century.

Georges Mathé (9 July 1922 – 15 October 2010) was a French oncologist and immunologist. In November 1958, he performed the first successful allogeneic bone marrow transplant ever performed on unrelated human beings.

Biography

Georges Mathé was born in 1922 in the village of Sermages, France, from a rural family. Selected by his village school master, he was sent to study in a boarding school in Moulins, Allier.

Education and early career

During World War II, he participated in the French Resistance, and studied to become a medical doctor in Paris. He graduated in 1950–51 with honors.

Oncology and bone marrow transplants

He engaged in medical research in the early fifties, and took an internship in immunology and oncology in the Memorial Sloan–Kettering Cancer Center, New York.

He specialised in hematology when working with Pr. Paul Chevallier and Pr. Jean Bernard, and devoting himself to child leukemia.

In November 1958, Mathé performed the first bone marrow graft between unrelated donors and hosts ever made in the world, in order to save six Yugoslavian nuclear researchers who had been accidentally irradiated. That event made him aware of the possibility and necessity of developing active and adoptive immunotherapy and applying it to the treatment of cancers.

He also participated with René Kuss and Marcel Legrain in 1960 and 61 to the first successful kidney grafts between non related donors and hosts.

By 1963 he "shook the medical world" when he announced he had cured a patient of leukemia by means of a bone marrow transplant. He later showed that stem cells could not only heal radiation damage, but also fight cancer. He also demonstrated the positive role of BCG combined with irradiated tumoral cells.

Georges Mathé took over the Hematology Department of the Institut Gustave Roussy in Villejuif in 1961 and created the Institut de Cancérologie et d’Immuno-génétique in 1964 where he created the first sterile hospital rooms. He also taught experimental oncology at the University of Paris (1966 to 1990), created and managed (from 1980 to 1988) the Service des Maladies Sanguines et Tumorales in the Hôpital Paul-Brousse where he blended research and therapy with groundbreaking methods and results in chemotherapy and immunotherapy to develop polytherapies adapted to individual cases.

He played a crucial role in the development of several important molecules such as acriflavine, bestatine, ellipticine, oxaliplatine, triptoreline and vinorelbine and actively participated in the development of polychemotherapy and chrono-chemotherapy.

Georges Mathé was one of the cofounders of the "Groupe Européen de Chimiothérapie Anticancéreuse" (G.E.C.A.) which was formally and legally established in 1962 by a group of European visionaries including Henri Tagnon, Silvio Garattini, Dirk van Bekkum, among others. Pr. Georges Mathé was the first President of GECA, from its creation in 1962 until 1965 and GECA became EORTC in 1968. In 1970, he was awarded the Cameron Prize for Therapeutics of the University of Edinburgh.

He also played a crucial role in the creation of the ARC in 1962, the INSERM in 1964, the CIRC in 1965, and the SMIC in 1975 which became the European Society for Medical Oncology (ESMO) in 1980.

Later career

In 1981, Mathé became a founding member of the World Cultural Council.

From 1990 to 2008, Mathé worked as a consultant at the Paris Swiss Hospital, at the Rome European Hospital, at the Sofia Oncological Hospital, at the Belgrade Civil Hospital and at the Hôpital Paul-Brousse.

In the early 1990s, conscious of the immunological nature of HIV/AIDS, Mathé applied immunotherapy to a dozen patients. He also successfully treated them with a cocktail of 5 alternating molecules, at a time when HIV/AIDS was considered ineluctably lethal and before the introduction of tritherapy.

All his life, he cooperated with researchers all around the world, particularly the US, Japan and, shortly before his death, China. He also chaired l’Entraide Médicale Internationale, which is devoted to improving African medicine.

He published more than a thousand articles and books, and received many international awards (Cameron Price, Gold Medal of the Ciba Foundation, Johan-Georg-Zimmermann Award, Health Memorial awards, Prix Bred du Cancer, International Award of chemotherapy, Gotlieb Memorial Award, Prix Leopold Griffuel du Cancer, Prix Medawar and Grande Médaille of the French Académie Nationale de Médecine).

Dr. Brian Bolwell, chief of hematology at the Cleveland Clinic noted that Dr. Mathé had proved an important principle: "You can cure an incurable leukemia patient.", and had developed both a technique and an important term, "adoptive immunotherapy," to describe how a person's own immune system can be used to combat cancer and other diseases.

Dr. Joseph H. Antin, chief of stem cell transplantation at the Dana-Farber Cancer Institute in Boston, summed up Mathé's work: "It was quite a leap of scientific genius. He’s one of the original innovators. Much of what we have accomplished can be linked back in a fairly direct way to the work that he did in the 1950s and ’60s”.

Death

Mathé died on October 15, 2010, at the Villejuif Hôpital Paul-Brousse, in France.

The Georges Mathé Award

The Georges Mathé Award was launched on March, 2010 by the Institut du Cancer et d'Immunogénétique (ICIG), to promote the therapeutic innovations and translational research initiated by Professor Georges Mathé. This annual distinction rewards a young researcher who has demonstrated audacity and originality in his / her work on the development of experimental and therapeutic research in the fields of cancer and immunology.

Tamim is the CEO and founder of Bondex and formerly ran a market advisory and recruitment firm for renewable energy industry vertical spanning Europe and North America, giving him first-hand knowledge of pain points/issues in the talent acquisition process. Tamim worked extensively with the LED chip business units of Samsung, LG, and Sharp; and helped build the executive teams in the US and Europe. He has been active within the crypto space since 2010. He holds a Bachelor's and Master's in economics and is a father of two.

Bondex is a next-generation, Web 3.0 talent ecosystem built by combining a talent network & marketplace partly owned by its community of users through tokenized rewards. Our priority is finding the best people, helping them make connections, and finding the right work opportunities.

Bondex began in January 2021. Its founding team members, with proven track records in recruitment and blockchain, HR tech, finance are uniquely qualified to deliver on the company mission.

Bondex Token

BNDX is a utility and governance token; and our native currency. The BNDX tokens will be paid as incentives to reward our users for network participation, referrals, growing our community, content creation, work, vesting.